News Otsuka has high hopes for its 'drug creation engine' acquisi... Otsuka is paying $430 million for a US clinical-stage biotech company it hopes will act as a ‘drug creation engine’ to accelerate its research into kidney diseases.
News EU approves AZ's potential blockbuster hyperkalaemia drug After manufacturing issues, AstraZeneca hopes for FDA nod soon.
News AZ signs kidney drug deal with Ionis for up to $330m Deal is result of six-year collaboration with AZ
News Alexion drug fails in kidney transplant trial Soliris fails when used to treat post-transplant complications.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.